1. Scrip

Torrent’s Entry Into Indian Trade Generics Signals Strategy Shift

US Launches Still Held Back

 
• By Vibha Ravi

Faced with a slowdown in the US from a lack of regulatory approvals, Torrent Pharma is looking at alternate growth strategies. Its entry into the trade generics segment in India, joining other pharma majors, is one to be watched as it marks a strategic shift.

Generic Medicines
Trade Generics In India See An Increase In Interest • Source: Alamy

Torrent Pharmaceuticals Ltd. has joined the league of pharma majors with a trade generics portfolio in India, a move likely triggered by a slow down in the US, its largest overseas market, as well as a consumer segment’s preference for cheaper alternatives to branded generics. 

The current government’s focus on providing economical drugs through “Pradhan Mantri Bhartiya Janaushadhi Kendras”, or public medical retail outlets, has been instrumental in driving Indian companies' interest in the segment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.